Albiglutide (trade name Eperzan) has been approved since March 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control.

June 12, 2012 (Philadelphia, Pennsylvania) — Once-weekly albiglutide has a more favorable tolerability profile than once-daily liraglutide, with similar effectiveness; however, albiglutide did ...

Senior Vice President, Biopharm Development, GlaxoSmithKline. "Albiglutide is a novel biological currently being investigated to determine its potential to help people control their blood sugar ...

GlaxoSmithKline (GSK) plc today announced a regulatory submission to the US Food and Drug Administration (US FDA) for albiglutide, an investigational once-weekly treatment for adult patients with ...

Albiglutide, an experimental diabetes drug that GlaxoSmithKline acquired when it bought Rockville-based Human Genome Sciences, proved effective in late-stage trials ...

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved TanzeumTM (albiglutide) for injection, for subcutaneous use, as a once-weekly ...

LONDON (Reuters) – GlaxoSmithKline said on Monday it had filed for U.S. approval of its new once-weekly diabetes drug albiglutide and would make a similar submission shortly in Europe as it vies ...